4.2 Article

Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients

期刊

AURIS NASUS LARYNX
卷 43, 期 1, 页码 1-9

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.anl.2015.08.015

关键词

Allergic rhinitis; Guideline; Subcutaneous immunotherapy; Sublingual immunotherapy

资金

  1. Astellas Pharma, Inc. (Tokyo, Japan)
  2. AstraZeneca K.K. (Osaka, Japan)
  3. Bayer Yakuhin, Ltd. (Osaka, Japan)
  4. Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan)
  5. Daiichi Sankyo Co., Ltd. (Tokyo, Japan)
  6. Dainippon Sumitomo Pharma Co., Ltd. (Osaka, Japan)
  7. Eisai Co., Ltd. (Tokyo, Japan)
  8. GlaxoSmithKline K.K. (Tokyo, Japan)
  9. Kissei Pharmaceutical Co., Ltd. (Matsumoto, Japan)
  10. Kyorin Pharmaceutical Co., Ltd. (Tokyo, Japan)
  11. Kyowa Hakko Kirin Co., Ltd. (Tokyo, Japan)
  12. Kowa Pharmaceutical Co., Ltd. (Nagoya, Japan)
  13. Merck & Co., Inc. (Kenilworth, NJ, USA)
  14. Mitsubishi Tanabe Pharma Co. (Osaka, Japan)
  15. Meiji Seika Pharma Co., Ltd. (Tokyo, Japan)
  16. Nikken Chemical Laboratory Co., Ltd. (Yokahama, Japan)
  17. Nippon Shinyaku Co., Ltd. (Kyoto, Japan)
  18. Nippon Boehringer Ingelheim Co., Ltd. (Tokyo, Japan)
  19. Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan)
  20. Ono Pharmaceutical Co., Ltd. (Tokyo, Japan)
  21. Pfizer Japan, Inc. (Tokyo, Japan)
  22. Sanofi Aventis K.K. (Tokyo, Japan)
  23. Shionogi Co., Ltd. (Osaka, Japan)
  24. Senju Pharmaceutical Co., Ltd. (Osaka, Japan)
  25. Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan)
  26. Takeda Pharmaceutical Co., Ltd. (Osaka, Japan)
  27. Taisho Toyama Pharmaceutical Co., Ltd (Tokyo, Japan)

向作者/读者索取更多资源

Objective: Sublingual immunotherapy (SLIT) appears to offer practical advantages for the treatment of allergic rhinitis (AR). Based on a review of the scientific literature, we present recommendations as guiding principles to administer SLIT safely. Methods: Clinical questions concerning SLIT were prepared. Literature published between January 2003 and December 2012 was searched from PubMed, the Cochrane Library, and Japana Centra Revuo Medicina. Qualified studies were analyzed and the results were evaluated, consolidated, and codified. We answered 17 clinical questions and, based on this, presented evidence-based recommendations. Results: Sublingual immunotherapy improved symptoms (e.g., quality of life [QOL]) and reduced medication scores in seasonal AR and perennial AR. Most SLIT-induced adverse effects were local oral reactions, although systemic adverse effects such as gastrointestinal symptoms, urticaria, and asthma are occasionally reported. There have been no reports of lethal anaphylactic reactions by SLIT. When SLIT is continued for 3-4 years, its effect persists long after discontinuation. Conclusion: A correct diagnosis of AR and sufficient informed consent from patients are required before initiating SLIT. Sublingual immunotherapy should be continued for 3 years or longer. The initial administration of SLIT during the uptitration of an allergen vaccine and the general condition of patients are critical for the safe performance of SLIT. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据